Clinicopathological analysis of primary refractory diffuse large B‐cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy

BACKGROUND: Approximately 15% of patients with diffuse large B‐cell lymphoma (DLBCL) experience refractory or early relapsed disease after initial rituximab‐containing chemoimmunotherapy is regarded as a primary refractory disease. Although the standard treatment for relapsed DLBCL is high‐dose chem...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Tomotaka, Maruyama, Dai, Miyagi‐Maeshima, Akiko, Nomoto, Junko, Tajima, Kinuko, Ito, Yuta, Hatta, Shunsuke, Yuda, Sayako, Makita, Shinichi, Fukuhara, Suguru, Munakata, Wataru, Suzuki, Tatsuya, Taniguchi, Hirokazu, Izutsu, Koji, Kobayashi, Yukio, Tobinai, Kensei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335825/
https://www.ncbi.nlm.nih.gov/pubmed/34105893
http://dx.doi.org/10.1002/cam4.4062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335825/
https://www.ncbi.nlm.nih.gov/pubmed/34105893
http://dx.doi.org/10.1002/cam4.4062

Ejemplares similares